Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Elagolix + E2/NETA in Uterine Fibroids
NCT03271489Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2017
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Uterine Fibroids (UF) comparing Elagolix + E2/NETA with Placebo -> Elagolix + E2/NETA (2 arms). Primary endpoint: Number of Participants With Adverse Events at 60 months. Started Sep 2017; status: completed.
02
Drugs
elagolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03271489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271489.